Athens Research & Technology Inc.

Established in 1986, the company has built a reputation for excellence in the quality of native proteins with high purity, offering a diverse research community of international diagnostic and pharmaceutical industry, academic research labs, the protein and enzyme reagent components to be used for in vitro diagnostics and immunoassay kits, as well as cell culture media application.

They have proven success in diagnostic assay development applications including Lipoproteins and Globulin Panel, HaemoglobinAc1 Standards and targeted disease tests for cardiovascular, pulmonary and autoimmune disorders.

Recognising that each diagnostic solutions can be unique, they have expanded their services to offer highly customised protein purification services and bulk protein development ensuring that these proteins efficiently integrate with various diagnostic assays and workflows. 

Athens makes every effort to retain active native protein structure and post-translational modifications, so it remains as it exists in the source tissue. Protocols are developed and tested to minimise deglycosylation and aggregation, and the technical support team ensures that customers receive all the answers specific to purification questions. 

With 39 years of experience as a high-quality native protein vendor they provide and offer 

• Custom services for Native Protein isolation from animal sera and tissues 
• Accomplished in the purification of proteins from other species and in the preparation of biotherapeutics for proof-of-concept studies in animal models.
• Range of Culture media growth supplements for Tissue Culture Grade ≥95% pure and ≤0.1 EU/mg and Bio-processing Grade - ≥98%pure, <1 EU/mg, <10 CFU/mg, and Heat Treated
• High purity Proteins for cellular function assessment 
• Proteins for Quality Control as standard calibration and control for cardiology, nephrology, diabetes and other disease state optimisation, for example they contribute to HDL and LDL cholesterol test panels.
• They have been primary suppliers for enzymes and inhibitors associated with blood disorders
• Antisera and positive controls for future Lateral Flow test commercialization are available